Ferroptosis in neurodegenerative diseases: mechanisms and therapeutic potential of stem cell derivatives

Ting Zhang, Yun Zhang, Jinpeng Xie, Dandan Lu, Lihong Wang, Shuaifei Zhao, Jing Zhou, Yang Cheng, Ting Kou, Jue Wang, Ying Chen, Lei Xu, Xiangyu Hu, Ying Yu, Jun Wang, Xiaozhou Xin, Siyun Lei, Chenyu Qiu, Jinhua Wu, Qiqi Lyu, Tong CaoFrontiers in Cell and Developmental Biology 2025 · DOI

Abstract

Ferroptosis, a non-apoptotic, iron-dependent form of regulated cell death, is closely related to the pathogenesis of neurodegenerative diseases. Stem cells and their derivatives exhibit remarkable potential in modulating ferroptosis, offering promising therapeutic intervention for neurodegenerative diseases. In this review, we systematically explore neurological aging and its association with cognitive impairment and neurodegenerative diseases, with focus on the molecular mechanisms of ferroptosis in neurodegenerative diseases and the potential therapeutic strategies of stem cell derivatives for neurological diseases.

Introduction

As the global population ages, the prevalence of neurodegenerative diseases (NDDs) such as Alzheimer’s (AD) and Parkinson’s (PD) is increasing rapidly. Historically, research into these conditions focused heavily on apoptosis (programmed cell death). However, many clinical trials based on this model have failed to produce effective treatments.

Recent evidence suggests that ferroptosis—a unique, iron-driven form of regulated cell death characterized by lipid peroxidation—plays a central role in the progression of NDDs. This review addresses the "ferroptosis gap," exploring how understanding this pathway can lead to novel therapies, particularly through the use of stem cell derivatives like exosomes, which offer a safer, more targeted way to deliver "anti-rust" signals to the brain than traditional cell transplants.

Molecular Mechanisms of Ferroptosis

The brain is uniquely vulnerable to ferroptosis due to its high iron demands, high oxygen consumption, and membranes rich in polyunsaturated fatty acids (PUFAs). Ferroptosis occurs when the cell's antioxidant defenses are overwhelmed, leading to the "rusting" of cell membranes through lipid peroxidation.

Schematic representation of the molecular pathways regulating ferroptosis, including iron metabolism, lipid peroxidation, and the antioxidant defense systems GPX4 and FSP1.

Key regulatory pathways identified in recent research include:

  • The GPX4 Pathway: Glutathione peroxidase 4 (GPX4) is the primary enzyme responsible for neutralizing lipid peroxides. Its activity depends on the availability of glutathione (GSH), which is regulated by the System xc- transporter.
  • The FSP1-CoQ10 Pathway: Ferroptosis-suppressor-protein 1 (FSP1) acts as a critical backup system to GPX4, using Coenzyme Q10 to inhibit lipid peroxidation at the membrane. This offers a secondary target for drug development.
  • The Nrf2 Pathway: Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of the antioxidant response, controlling the expression of numerous genes involved in iron metabolism and redox balance.

Ferroptosis in Neurodegenerative Diseases

Iron dysregulation manifests differently across various NDDs, but the underlying mechanism of ferroptosis remains a common thread. In Alzheimer’s Disease, iron accumulation in the hippocampus and cortex correlates with cognitive decline and GPX4 depletion. In Parkinson’s Disease, the accumulation of $\alpha$-synuclein protein suppresses Nrf2, creating a deadly feedback loop that increases susceptibility to ferroptosis in dopaminergic neurons. Similarly, postmortem data from ALS and Huntington’s patients show significant iron overload and lipid peroxidation in the spinal cords and brain tissue.

Stem Cell Derivatives: A New Therapeutic Frontier

While stem cell transplantation shows promise, it carries risks such as tumor formation and immune rejection. Stem cell-derived exosomes are emerging as a sophisticated "cell-free" alternative. These nanoscale vesicles can cross the blood-brain barrier, possess low immunogenicity, and can be engineered to carry specific therapeutic cargo, such as microRNAs (miRNAs) designed to trigger antioxidant defenses.

Key results from recent studies include:

  • Cognitive Recovery: MSC-derived exosomes activated the SIRT1/Nrf2/HO-1 pathway in aged mice, significantly improving cognitive dysfunction.
  • Stroke Intervention: Intranasal delivery of exosomes enriched with miR-760-3p reduced lipid peroxidation and improved neurobehavioral function in ischemia/reperfusion injury models.
  • Spinal Cord Repair: Engineered exosomes carrying circ-Wdfy3 were shown to upregulate GPX4 and reduce neuronal death after spinal cord injury.
  • ALS Delay: Overexpressing GPX4 in transgenic ALS mice notably delayed disease onset and prolonged lifespan, proving that ferroptosis is a viable therapeutic target.

Challenges and Future Outlook

Despite the potential of exosome-based therapies, several hurdles remain. Most current research focuses on Mesenchymal Stem Cells (MSCs), leaving a gap regarding derivatives from neural stem cells or pluripotent stem cells. Furthermore, improving the targeting precision of these vesicles to ensure they reach specific types of neurons or glial cells is essential. Future large-scale clinical trials are needed to determine the optimal dosage and long-term safety of engineered exosome therapies in humans.

Summary updated

Abstract

Ferroptosis, a non-apoptotic, iron-dependent form of regulated cell death, is closely related to the pathogenesis of neurodegenerative diseases. Stem cells and their derivatives exhibit remarkable potential in modulating ferroptosis, offering promising therapeutic intervention for neurodegenerative diseases. In this review, we systematically explore neurological aging and its association with cognitive impairment and neurodegenerative diseases, with focus on the molecular mechanisms of ferroptosis in neurodegenerative diseases and the potential therapeutic strategies of stem cell derivatives for neurological diseases.
BibTeX
@inproceedings{zhang2025ferroptosis,
  author = {Ting Zhang and Yun Zhang and Jinpeng Xie and Dandan Lu and Lihong Wang and Shuaifei Zhao and Jing Zhou and Yang Cheng and Ting Kou and Jue Wang and Ying Chen and Lei Xu and Xiangyu Hu and Ying Yu and Jun Wang and Xiaozhou Xin and Xu Xu and Siyun Lei and Chenyu Qiu and Jinhua Wu and Qiqi Lyu and Tong Cao},
  title = {{Ferroptosis in neurodegenerative diseases: mechanisms and therapeutic potential of stem cell derivatives}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  doi = {10.3389/fcell.2025.1577382},
}
Figure